ACTRN12609000642280招募中3 期
A pilot study evaluating the impact of Taxotere, Cisplatin and 5-Fluorouracil (TPF) induction chemotherapy on intratumoral hypoxia in locoregionally advanced head and neck squamous cell cancer
Peter MacCallum Cancer Centre0 个研究点目标入组 25 人开始时间: 2009年7月30日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Aged 18 years or older
- •- previously untreated squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx
- •- Histologically or cytologically confirmed squamous cell carcinoma
- •- stage 3 or 4 disease
- •- adequate hematological, renal, hepatic and pulmonary function
- •- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1
- •- measurable disease by Response Evaluation Criteria in Solid Tumours (RECIST) criteria
- •- creatinine clearance > or = 60ml/min
排除标准
- •- women who are pregnant or lactating
- •- previous radiotherapy to area to be treated
- •- prior diagnosis of cancer
- •- clinical evidence of metastatic disease
- •- pre existing motor or sensory neurotoxicity or neuropathy > or = grade 1
- •- clinically significant sensorineural hearing loss
- •- active uncontrolled infection
- •- unstable cardiac disease requirin treatment
研究者
相似试验
进行中（未招募）
不适用
A Pilot Phase II combination study of Taxotere (Docetaxel) and Erbitux (Cetuximab) as a NEOadjuvant therapy in patients with triple-negative” (HR and Her2 negative) operable breast cancer. TENEO Study - TENEO studyCancer du sein opérable RH- et Her2-, en situation néoadjuvanteMedDRA version: 9.1Level: LLTClassification code 10022882Term: Invasive ductal breast cancerEUCTR2007-002371-13-FRCentre Jean Perrin
已完成
3 期
BCIRG 007 / ANZBCTG 0102A phase III trial to evaluate Taxotere® and Herceptin® Vs Taxotere®, Carboplatin and Herceptin® as First Line Chemotherapy in Metastatic Breast Cancer patients containing the Her2 Gene Amplification.Cancer - BreastBreast CancerACTRN12607000032459Roche pharmaceuticals263
Unknown
1 期
TaxXel: Taxotere and Xeloda in Esophageal CancerCancer of the EsophagusGastric Cardia CarcinomaNCT00821912Karolinska University Hospital93
已完成
1 期
Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) PatientsNSCLCNCT00072618Astellas Pharma Inc52
进行中（未招募）
不适用
A Pilot Study of Taxotere (Docetaxel), Cisplatin and 5FU (TPF) in the Palliative Treatment of Squamous Cell Carcinoma of the Head and Neck - tinpatocally recurrent or metastatic squamous call carcinoma of the head and neckEUCTR2006-005816-29-GBRoyal Wolverhampton Hospitals Trust25